Loading publications…
The last 5 uploaded publications
CXCR2 inhibition enables NASH-HCC immunotherapy
Jack Leslie, John B. G. Mackey, Thomas Jamieson, Erik Ramón-Gil, Thomas M. Drake, Frédéric Fercoq, William Clark, Kathryn Gilroy, Ann Hedley, Colin Nixon, Saimir Luli, Maja Laszczewska, Roser Pinyol, Roger Esteban-Fabró, Catherine E. Willoughby, Philipp K. Haber, Carmen Andreu-Oller, Mohammad Rahbari, Chaofan Fan, Dominik Pfister, Shreya Raman, Niall Wilson, Miryam Müller, Amy Collins, Daniel Geh, Andrew Fuller, David McDonald, Gillian Hulme, Andrew Filby, Xabier Cortés-Lavaud, Noha-Ehssan Mohamed, Catriona A. Ford, Ximena L. Raffo Iraolagoitia, Amanda J. McFarlane, Misti McCain, Rachel A. Ridgway, Edward W. Roberts, Simon T. Barry, Gerard J. Graham, Mathias Heikenwälder, Helen L. Reeves, Josep M. Llovet, Leo M. Carlin, Thomas G. Bird, Owen J. Sansom, Derek A. Mann (2022). CXCR2 inhibition enables NASH-HCC immunotherapy. Gut, 71(10), pp. 2093-2106, DOI: 10.1136/gutjnl-2021-326259.
Article145 days agoHuman-correlated genetic models identify precision therapy for liver cancer
Miryam Müller, Stephanie May, H. G. HALL, Timothy J. Kendall, Lynn McGarry, Lauriane Blukacz, Sandro Nuciforo, Αναστασία Γεωργακοπούλου, Thomas Jamieson, Narisa Phinichkusolchit, Sandeep Dhayade, Toshiyasu Suzuki, Júlia Huguet‐Pradell, Ian R. Powley, Leah Officer-Jones, Rachel Pennie, Roger Esteban-Fabró, Albert Gris‐Oliver, Roser Pinyol, George Skalka, Jack Leslie, Matthew Hoare, Joep Sprangers, Gaurav Malviya, Agata Mackintosh, Emma Johnson, Misti McCain, John Halpin, Christos Kiourtis, Colin Nixon, Graeme M. Clark, William R. Clark, Robin Shaw, Ann Hedley, Thomas M. Drake, Ee Hong Tan, Matt Neilson, Daniel J. Murphy, David Y. Lewis, Helen L. Reeves, John Le Quesne, Derek A. Mann, Leo M. Carlin, Karen Blyth, Josep M. Llovet, Markus H. Heim, Owen J. Sansom, Crispin Miller, Thomas G. Bird (2025). Human-correlated genetic models identify precision therapy for liver cancer. Nature, DOI: 10.1038/s41586-025-08585-z.
Article145 days agoCXCR2 inhibition enables NASH-HCC immunotherapy
Jack Leslie, John B. G. Mackey, Thomas Jamieson, Erik Ramón-Gil, Thomas M. Drake, Frédéric Fercoq, William Clark, Kathryn Gilroy, Ann Hedley, Colin Nixon, Saimir Luli, Maja Laszczewska, Roser Pinyol, Roger Esteban-Fabró, Catherine E. Willoughby, Philipp K. Haber, Carmen Andreu-Oller, Mohammad Rahbari, Chaofan Fan, Dominik Pfister, Shreya Raman, Niall Wilson, Miryam Müller, Amy Collins, Daniel Geh, Andrew Fuller, David McDonald, Gillian Hulme, Andrew Filby, Xabier Cortés-Lavaud, Noha-Ehssan Mohamed, Catriona A. Ford, Ximena L. Raffo Iraolagoitia, Amanda J. McFarlane, Misiti McCain, Rachel A. Ridgway, Edward W. Roberts, Simon T. Barry, Gerard J. Graham, Mathias Heikenwälder, Helen L. Reeves, Josep M. Llovet, Leo M. Carlin, Thomas G. Bird, Owen J. Sansom, Derek A. Mann (2022). CXCR2 inhibition enables NASH-HCC immunotherapy. bioRxiv (Cold Spring Harbor Laboratory), DOI: 10.1101/2022.02.24.481779.
Preprint145 days ago